SrasV1, 2020, Analysis, bibRecord, 000167

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.

Identifieur interne : 000167 ( 2020/Analysis ); précédent : 000166; suivant : 000168

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.

Auteurs : Leon Caly [Australie] ; Julian D. Druce [Australie] ; Mike G. Catton [Australie] ; David A. Jans [Australie] ; Kylie M. Wagstaff [Australie]

Source :

Antiviral research [ 1872-9096 ] ; 2020.

RBID : pubmed:32251768

Abstract

Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection with SARS-CoV-2 able to effect ~5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans.

DOI: 10.1016/j.antiviral.2020.104787
PubMed: 32251768

Affiliations:

Australie

Links to Exploration step

pubmed:32251768

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.</title>
<author><name sortKey="Caly, Leon" sort="Caly, Leon" uniqKey="Caly L" first="Leon" last="Caly">Leon Caly</name>
<affiliation wicri:level="1"><nlm:affiliation>Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, At the Peter Doherty Institute for Infection and Immunity, Victoria, 3000, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, At the Peter Doherty Institute for Infection and Immunity, Victoria, 3000</wicri:regionArea>
<wicri:noRegion>3000</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Druce, Julian D" sort="Druce, Julian D" uniqKey="Druce J" first="Julian D" last="Druce">Julian D. Druce</name>
<affiliation wicri:level="1"><nlm:affiliation>Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, At the Peter Doherty Institute for Infection and Immunity, Victoria, 3000, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, At the Peter Doherty Institute for Infection and Immunity, Victoria, 3000</wicri:regionArea>
<wicri:noRegion>3000</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Catton, Mike G" sort="Catton, Mike G" uniqKey="Catton M" first="Mike G" last="Catton">Mike G. Catton</name>
<affiliation wicri:level="1"><nlm:affiliation>Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, At the Peter Doherty Institute for Infection and Immunity, Victoria, 3000, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, At the Peter Doherty Institute for Infection and Immunity, Victoria, 3000</wicri:regionArea>
<wicri:noRegion>3000</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jans, David A" sort="Jans, David A" uniqKey="Jans D" first="David A" last="Jans">David A. Jans</name>
<affiliation wicri:level="1"><nlm:affiliation>Biomedicine Discovery Institute, Monash University, Clayton, Vic, 3800, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Biomedicine Discovery Institute, Monash University, Clayton, Vic, 3800</wicri:regionArea>
<wicri:noRegion>3800</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wagstaff, Kylie M" sort="Wagstaff, Kylie M" uniqKey="Wagstaff K" first="Kylie M" last="Wagstaff">Kylie M. Wagstaff</name>
<affiliation wicri:level="1"><nlm:affiliation>Biomedicine Discovery Institute, Monash University, Clayton, Vic, 3800, Australia. Electronic address: kylie.wagstaff@monash.edu.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Biomedicine Discovery Institute, Monash University, Clayton, Vic, 3800</wicri:regionArea>
<wicri:noRegion>3800</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32251768</idno>
<idno type="pmid">32251768</idno>
<idno type="doi">10.1016/j.antiviral.2020.104787</idno>
<idno type="wicri:Area/PubMed/Corpus">000333</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000333</idno>
<idno type="wicri:Area/PubMed/Curation">000333</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000333</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000137</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000137</idno>
<idno type="wicri:Area/Ncbi/Merge">003766</idno>
<idno type="wicri:Area/Ncbi/Curation">003766</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">003766</idno>
<idno type="wicri:Area/Main/Merge">000167</idno>
<idno type="wicri:Area/Main/Curation">000167</idno>
<idno type="wicri:Area/Main/Exploration">000167</idno>
<idno type="wicri:Area/2020/Extraction">000167</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.</title>
<author><name sortKey="Caly, Leon" sort="Caly, Leon" uniqKey="Caly L" first="Leon" last="Caly">Leon Caly</name>
<affiliation wicri:level="1"><nlm:affiliation>Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, At the Peter Doherty Institute for Infection and Immunity, Victoria, 3000, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, At the Peter Doherty Institute for Infection and Immunity, Victoria, 3000</wicri:regionArea>
<wicri:noRegion>3000</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Druce, Julian D" sort="Druce, Julian D" uniqKey="Druce J" first="Julian D" last="Druce">Julian D. Druce</name>
<affiliation wicri:level="1"><nlm:affiliation>Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, At the Peter Doherty Institute for Infection and Immunity, Victoria, 3000, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, At the Peter Doherty Institute for Infection and Immunity, Victoria, 3000</wicri:regionArea>
<wicri:noRegion>3000</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Catton, Mike G" sort="Catton, Mike G" uniqKey="Catton M" first="Mike G" last="Catton">Mike G. Catton</name>
<affiliation wicri:level="1"><nlm:affiliation>Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, At the Peter Doherty Institute for Infection and Immunity, Victoria, 3000, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, At the Peter Doherty Institute for Infection and Immunity, Victoria, 3000</wicri:regionArea>
<wicri:noRegion>3000</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jans, David A" sort="Jans, David A" uniqKey="Jans D" first="David A" last="Jans">David A. Jans</name>
<affiliation wicri:level="1"><nlm:affiliation>Biomedicine Discovery Institute, Monash University, Clayton, Vic, 3800, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Biomedicine Discovery Institute, Monash University, Clayton, Vic, 3800</wicri:regionArea>
<wicri:noRegion>3800</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wagstaff, Kylie M" sort="Wagstaff, Kylie M" uniqKey="Wagstaff K" first="Kylie M" last="Wagstaff">Kylie M. Wagstaff</name>
<affiliation wicri:level="1"><nlm:affiliation>Biomedicine Discovery Institute, Monash University, Clayton, Vic, 3800, Australia. Electronic address: kylie.wagstaff@monash.edu.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Biomedicine Discovery Institute, Monash University, Clayton, Vic, 3800</wicri:regionArea>
<wicri:noRegion>3800</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Antiviral research</title>
<idno type="eISSN">1872-9096</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection with SARS-CoV-2 able to effect ~5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans.</div>
</front>
</TEI>
<affiliations><list><country><li>Australie</li>
</country>
</list>
<tree><country name="Australie"><noRegion><name sortKey="Caly, Leon" sort="Caly, Leon" uniqKey="Caly L" first="Leon" last="Caly">Leon Caly</name>
</noRegion>
<name sortKey="Catton, Mike G" sort="Catton, Mike G" uniqKey="Catton M" first="Mike G" last="Catton">Mike G. Catton</name>
<name sortKey="Druce, Julian D" sort="Druce, Julian D" uniqKey="Druce J" first="Julian D" last="Druce">Julian D. Druce</name>
<name sortKey="Jans, David A" sort="Jans, David A" uniqKey="Jans D" first="David A" last="Jans">David A. Jans</name>
<name sortKey="Wagstaff, Kylie M" sort="Wagstaff, Kylie M" uniqKey="Wagstaff K" first="Kylie M" last="Wagstaff">Kylie M. Wagstaff</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/2020/Analysis

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000167 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd -nk 000167 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    2020
   |étape=   Analysis
   |type=    RBID
   |clé=     pubmed:32251768
   |texte=   The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/RBID.i   -Sk "pubmed:32251768" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

Serveur d'exploration SRAS

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.

Source :

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.